The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients

American Journal of Obstetrics and Gynecology

Volumn 206, Issue 1, 2012, Pages 58.e1-58.e8

  Verlohren, Stefan ^a   Herraiz, Ignacio ^e   Lapaire, Olav ^f   Schlembach, Dietmar ^g   Moertl, Manfred ^g   Zeisler, Harald ^h   Calda, Pavel ⁱ   Holzgreve, Wolfgang ^b   Galindo, Alberto ^e   Engels, Theresa ^a   Denk, Barbara ^c   Stepan, Holger ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Institute for Advanced Study Berlin   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f UNIVERSITY OF BASEL   (Switzerland)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

Author keywords

gestational hypertension; PIGF; placental growth factor; preeclampsia; sFlt 1; singleton pregnancy; soluble fms like tyrosine kinase

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC HYPERTENSION; CONTROLLED STUDY; DELIVERY; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROGNOSIS;

EID: 84455208308     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2011.07.037     Document Type: Article

References (40)

1. K.S. Khan, D. Wojdyla, L. Say, A.M. Gulmezoglu, P.F. Van Look WHO analysis of causes of maternal death: a systematic review Lancet 367 2006 1066 1074
2. L. Duley The global impact of pre-eclampsia and eclampsia Semin Perinatol 33 2009 130 137
3. C.J. Berg, A.P. Mackay, C. Qin, W.M. Callaghan Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005 Obstet Gynecol 113 2009 1075 1081
4. J.M. Roberts, G.D. Pearson, J.A. Cutler, M.D. Lindheimer Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy Hypertens Pregnancy 22 2003 109 127
5. B.M. Sibai Diagnosis and management of gestational hypertension and preeclampsia Obstet Gynecol 102 2003 181 192
6. F. Milne, C. Redman, J. Walker The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community BMJ 330 2005 576 580
7. M.D. Lindheimer, S.J. Taler, F.G. Cunningham ASH position paper: hypertension in pregnancy J Clin Hypertens (Greenwich) 11 2009 214 225
8. M.D. Lindheimer, S.J. Taler, F.G. Cunningham Hypertension in pregnancy J Am Soc Hypertens 2 2008 484 494
9. American College of Obstetricians and Gynecologists ACOG practice bulletin no. 33, Jan. 2002 Diagnosis and management of preeclampsia and eclampsia Obstet Gynecol 99 2002 159 167
10. U.M. Reddy, C.W. Ko, T.N. Raju, M. Willinger Delivery indications at late-preterm gestations and infant mortality rates in the United States Pediatrics 124 2009 234 240
11. M. Sanderson, W.M. Sappenfield, K.M. Jespersen, Q. Liu, S.L. Baker Association between level of delivery hospital and neonatal outcomes among South Carolina Medicaid recipients Am J Obstet Gynecol 183 2000 1504 1511
12. M.M. Bode, T.M. O'Shea, K.R. Metzguer, A.D. Stiles Perinatal regionalization and neonatal mortality in North Carolina, 1968-1994 Am J Obstet Gynecol 184 2001 1302 1307
13. American College of Obstetricians and Gynecologists ACOG committee opinion Antenatal corticosteroid therapy for fetal maturation Int J Gynaecol Obstet 78 2002 95 97
14. L. Duley, B. Farrell Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial Lancet 359 2002 1877 1890
15. G. Dekker, B. Sibai Primary, secondary, and tertiary prevention of pre-eclampsia Lancet 357 2001 209 215
16. Maulik D, Mundy D, Heitmann E. Evidence-based approach to umbilical artery Doppler fetal surveillance in high-risk pregnancies: an update. Clin Obstet Gynecol 53:869-78.
17. T.A. Moore Simas, S.L. Crawford, M.J. Solitro, S.C. Frost, B.A. Meyer, S.E. Maynard Angiogenic factors for the prediction of preeclampsia in high-risk women Am J Obstet Gynecol 197 2007 244.e1 244.e8
18. F. Herse, S. Verlohren, K. Wenzel Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study Hypertension 53 2009 393 398
19. A.C. Staff, K. Braekke, N.K. Harsem, T. Lyberg, M.R. Holthe Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia Eur J Obstet Gynecol Reprod Biol 122 2005 33 39
20. C.J. Robinson, D.D. Johnson, E.Y. Chang, D.M. Armstrong, W. Wang Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia Am J Obstet Gynecol 195 2006 255 259
21. H. Stepan, A. Unversucht, N. Wessel, R. Faber Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion Hypertension 49 2007 818 824
22. J. Espinoza, R. Romero, J.K. Nien Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor Am J Obstet Gynecol 196 2007 326.e1 326.e13
23. J.P. Kusanovic, R. Romero, T. Chaiworapongsa A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia J Matern Fetal Neonatal Med 22 2009 1021 1038
24. R. Romero, J.K. Nien, J. Espinoza A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate J Matern Fetal Neonatal Med 21 2008 9 23
25. R.J. Levine, C. Lam, C. Qian Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 2006 992 1005
26. X.Y. Zhong, W. Holzgreve, S. Hahn The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia Hypertens Pregnancy 21 2002 77 83
27. S. Verlohren, A. Galindo, D. Schlembach An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia Am J Obstet Gynecol 202 2010 161.e1 161.e11
28. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy Am J Obstet Gynecol 183 2000 S1 S22
29. B.M. Sibai, J.R. Barton Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications Am J Obstet Gynecol 196 2007 514.e1 514.e9
30. E. Schneider, A. Gleixner, R. Hnel Technical performance of the first fully automated assays for soluble fms-like tyrosine kinase 1 and human placental growth factor Z Geburtsh Neonatol 213 2009 69
31. S. Salahuddin, Y. Lee, M. Vadnais, B.P. Sachs, S.A. Karumanchi, K.H. Lim Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy Am J Obstet Gynecol 197 2007 28.e1 28.e6
32. V.D. Nadarajah, R.G. Min, J.P. Judson, R. Jegasothy, E.H. Ling Maternal plasma soluble fms-like tyrosine kinase-1 and placental growth factor levels as biochemical markers of gestational hypertension for Malaysian mothers J Obstet Gynaecol Res 35 2009 855 863
33. S.K. Nadar, I. Karalis, E. Al Yemeni, A.D. Blann, G.Y. Lip Plasma markers of angiogenesis in pregnancy induced hypertension Thromb Haemost 94 2005 1071 1076
34. M. Noori, A.E. Donald, A. Angelakopoulou, A.D. Hingorani, D.J. Williams Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension Circulation 122 2010 478 487
35. B.M. Sibai, M.A. Koch, S. Freire The impact of prior preeclampsia on the risk of superimposed preeclampsia and other adverse pregnancy outcomes in patients with chronic hypertension Am J Obstet Gynecol 204 2011 345.e1 345.e6
36. B.M. Sibai, M.A. Koch, S. Freire, J.L. Pinto e Silva Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 199 2008 268.e1 268.e9
37. Y.N. Kim, D.S. Lee, D.H. Jeong, M.S. Sung, K.T. Kim The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia Prenat Diagn 29 2009 464 470
38. R. Troisi, K. Braekke, N.K. Harsem, M. Hyer, R.N. Hoover, A.C. Staff Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies Am J Obstet Gynecol 199 2008 653.e1 653.e10
39. A. Molvarec, A. Szarka, S. Walentin, E. Szucs, B. Nagy, J. Rigo Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia Hypertens Res 33 2010 892 898
40. J. Zhang, M.A. Klebanoff, J.M. Roberts Prediction of adverse outcomes by common definitions of hypertension in pregnancy Obstet Gynecol 97 2001 261 267